Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein

American Journal of Physiology

Volumn 277, Issue 4 PART 1, 1999, Pages

  Illek, Beate ^a   Zhang, Lei ^b   Lewis, Nancy C ^a   Moss, Richard B ^c   Dong, Jian Yun ^b   Fischer, Horst ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cystic fibrosis transmembrane conductance regulator mutations; Flavonoids; Nasal potential difference; Patch clamp

Indexed keywords

4 PHENYLBUTYRIC ACID; FORSKOLIN; GENISTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

ARTICLE; CYSTIC FIBROSIS; HUMAN; HUMAN CELL; MISSENSE MUTATION; NORMAL HUMAN; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN PROCESSING; RECEPTOR UPREGULATION;

BIOLOGICAL TRANSPORT; CHILD, PRESCHOOL; CHLORIDES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENISTEIN; HELA CELLS; HUMANS; MUTATION, MISSENSE; PATCH-CLAMP TECHNIQUES;

EID: 0032743305     PISSN: 00029513     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpcell.1999.277.4.c833     Document Type: Article

References (29)

1. Arispe, N., J. Ma, K. A. Jacobson, and H. B. Pollard. Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-diallyl-8-cyclohexykanthine (DAX). J. Biol. Chem. 273: 5727-5734, 1998.
2. Brown, C. R., L. Q. Hong-Brown, J. Biwersi, A. S. Verkman, and W. J. Welch. Chemical chaperones correct the mutant phenotype of the ΔF508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones 1: 117-125, 1996.
3. Cashman, S. M., A. Patino, M. G. Delgado, L. Byrne, B. Denham, and M. De Arce. The Irish cystic fibrosis database. J. Med. Genet. 32: 972-975, 1995.
4. Chappe, V., Y. Mettey, J. M. Vierfond, J. W. Hanrahan, M. Gola, B. Verrier, and F. Becq. Structural basis for specificity and potency of xanthine derivatives as activators of the CFTR chloride channel. Br. J. Pharmacol. 123: 683-693, 1998.
5. Dorin, J. R., R. Farley, S. Webb, S. N. Smith, E. Farini, S. J. Delaney, B. J. Wainwright, E. W. Alton, and D. J. Porteous. A demonstration using mouse models that successful gene therapy for cystic fibrosis requires only partial gene correction. Gene Ther. 3: 797-801, 1996.
6. Drumm, M. L., H. A. Pope, W. H. Cliff, J. A. Rommens, S. A. Marvin, L.-C. Tsui, F. A. Collins, R. A. Frizzell, and J. A. Wilson. Correction of the cystic fibrosis defectin vitro by retrovirus-mediated gene transfer. Cell 62: 1227-1233, 1990.
7. Fischer, H., and T. E. Machen. CFTR displays voltage dependence and two gating modes during stimulation. J. Gen. Physiol. 104: 541-566, 1994.
8. Fischer, H., and T. E. Machen. The tyrosine kinase p60c-src regulates the fast gate of the cystic fibrosis transmembrane conductance regulator chloride channel. Biophys. J. 71: 3073-3082, 1996.
9. Gimbovskaia, S. D., V. N. Kalinin, T. E. Ivashchenko, and V. S. Baranov. Molecular-genetic analysis of certain mutations of the "cystic fibrosis gene" in Moldavia. Characteristics of molecular markers and their linkage with various mutations. Genetika 30: 1616-1620, 1994.
10. Graham, F. L., and L. Prevec. Adenovirus-based expression vectors and recombinant vaccines. Biotechnology 20: 363-390, 1992.
11. Greil, I., K. Wagner, E. Eber, M. Zach, and W. Rosenkranz. Molecular and clinical findings in Austrian cystic fibrosis patients with mutations in exon 11 of the CFTR gene. Wien Klin. Wochenschr. 107: 464-469, 1995.
12. Hamosh, A., T. M. King, B. J. Rosenstein, M. Corey, H. Levison, P. Durie, L. C. Tsui, I. McIntosh, M. Keston, D. J. Brock, et al. Cystic fibrosis patients bearing both the common missense mutation Gly - Asp at codon 551 and the ΔF508 mutation are clinically indistinguishable from ΔF508 homozygotes, except for decreased risk of meconium ileus. Am. J. Hum. Genet. 51: 245-250, 1992.
13. Highsmith, W. E., Jr., L. H. Burch, Z. Zhou, J. C. Olsen, T. V. Strong, T. Smith, K. J. Friedman, L. M. Silverman, R. C. Boucher, F. S. Collins, and M. R. Knowles. Identification of a splice site mutation (2789+5 G > A) associated with small amounts of normal CFTR mRNA and mild cystic fibrosis. Hum. Mutat. 9: 332-338, 1997.
14. Howard, M., R. A. Frizzell, and D. M. Bedwell. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat. Med. 2: 467-469, 1996.
15. Illek, B., and H. Fischer. Flavonoids stimulate Cl conductance of human airway epithelium in vitro and in vivo. Am. J. Physiol. 275 (Lung Cell. Mol. Physiol. 19): L902-L910, 1998.
16. Jefferson, D. M., J. D. Valentich, F. C. Marini, S. A. Grubman, M. C. Iannuzzi, H. L. Dorkin, M. Li, K. W. Klinger, and M. J. Welsh. Expression of normal and cystic fibrosis phenotypes by continuous airway epithelial cell lines. Am. J. Physiol. 259 (Lung Cell. Mol. Physiol. 3): L496-L505, 1990.
17. Jiang, C., S. L. Fang, Y.-F. Xiao, S. P. O'Connor, S. G. Nadler, D. W. Lee, D. M. Jefferson, J. M. Kaplan, A. E. Smith, and S. H. Cheng. Partial restoration of cAMP-stimulated CFTR chloride channel activity in ΔF508 cells by deoxyspergualin. Am. J. Physiol. 275 (Cell Physiol. 44): C171-C178, 1998.
18. Johnson, L. G., J. C. Olsen, B. Sarkadi, K. L. Moore, R. Swanstrom, and R. C. Boucher. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat. Genet. 2: 21-25, 1992.
19. Kelley, T. J., K. Thomas, L. J. Milgram, and M. L. Drumm. In vivo activation of the cystic fibrosis transmembrane conductance regulator mutant ΔF508 in murine nasal epithelium. Proc. Natl. Acad. Sci. USA 94: 2604-2608, 1997.
20. Knowles, M. R., A. M. Paradiso, and R. C. Boucher. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum. Gene Ther. 6: 445-455, 1995.
21. Logan, J., D. Hiestand, P. Daram, Z. Huang, D. D. Muccio, J. Hartman, B. Haley, W. J. Cook, and E. J. Sorscher. Cystic fibrosis transmembrane conductance regulator mutations that disrupt nucleotide binding. J. Clin. Invest. 94: 228-236, 1994.
22. Parad, R. B. Heterogeneity of phenotype in two cystic fibrosis patients homozygous for the CFTR exon 11 mutation G551D. J. Med. Genet. 33: 711-713, 1996.
23. Qu, B. H., E. H. Strickland, and P. J. Thomas. Localization and suppression of a kinetic defect in cystic fibrosis transmembrane conductance regulator folding. J. Biol. Chem. 272: 15739-15744, 1997.
24. Rubenstein, R. C., M. E. Egan, and P. L. Zeitlin. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing ΔF508-CFTR. J. Clin. Invest. 100: 2457-2465, 1997.
25. The Cystic Fibrosis Genetic Analysis Consortium. Cystic fibrosis mutation database. Cystic fibrosis mutation distribution by continent. [Online] The Cystic Fibrosis Genetic Analysis Consortium. http://www.genet.sickkids.on.ca/sftr/rptTable2.html [1998]
26. Tummler, B., T. Storrs, V. Dziadek, T. Dork, T. Meitinger, A. Golla, R. M. Bertele-Harms, H. K. Harms, E. Schroder, A. Claass, J. Rutjes, R. Schneppenheim, I. Bauer, K. Breuel, M. Stuhrmann, J. Schmidtke, M. Lindner, A. Eigel, J. Horst, R. Kaiser, M. J. Lentze, K. Schmidt, H. von der Hardt, and X. Estivill. Geographic distribution and origin of CFTR mutations in Germany. Hum. Genet. 97: 727-731, 1996.
27. Welsh, M. J., and A. E. Smith. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73: 1251-1254, 1993.
28. 2+ ionophores in cystic fibrosis airway epithelia. Am. J. Physiol. 256 (Cell Physiol. 25): C226-C233, 1989.
29. Willumsen, N. J., and R. C. Boucher. Shunt resistance and ion permeabilities in normal and cystic fibrosis airway epithelia. Am. J. Physiol. 256 (Cell Physiol. 25): C1054-C1063, 1989.